Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 601–700 of 1,003
Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling
Broek, R. V., Snow, G. E., Chen, Z., & Waes, C. V. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.10.005 · Cited by 61
“Another reason COX-2 inhibitors have not found great acceptance in the clinic for HNSCC chemoprevention is that they are associated with adverse cardiovascular events, which has led to the suspension or discontinuation of several clinical trials [135].”
BackgroundBridge Between Neuroimmunity and Traumatic Brain Injury
Kelso, M. L., & Gendelman, H. E. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113196660653 · Cited by 57
Myths and facts in the use of anti-inflammatory drugs
Hunt, R. H., Lanas, A., Stichtenoth, D. O., & Scarpignato, C. (2009) · Annals of Medicine · doi:10.1080/07853890902887295 · Cited by 55
“Cyclo-oxygenase 2 (COX-2)-selective inhibitors (often referred to as coxibs (15)) were introduced as a safer alternative to traditional NSAIDs (tNSAIDs) based on an improved GI safety profile but were subsequently found to be associated with an increase in cardiovascular (CV) adverse events (16,17).”
BackgroundElyasi, S., Rezazadeh‐Shojaee, F., Allahyari, A., & Karimi, G. (2017) · Phytotherapy Research · doi:10.1002/ptr.5857 · Cited by 57
“However, many trials have currently been stopped because of data suggesting an increased risk of cardiovascular risks (myocardial infarction, stroke, or heart failure) associated with these medications (Bresalier et al., 2005; Nussmeier et al., 2005; Solomon et al., 2005).”
BackgroundSolomon, D. H., Husni, M. E., Wolski, K. E., Wisniewski, L. M., BORER, J. S., Graham, D. Y., Libby, P., Lincoff, A. M., Lüscher, T. F., Menon, V., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40400 · Cited by 57
The Role of Topical Cyclo-Oxygenase-2 Inhibitors in Skin Cancer
Zhan, H., & Zheng, H. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708040-00002 · Cited by 57
Wu, Y., & Guo, S. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2006.07.034 · Cited by 61
“Unfortunately, with the very recent report that the use of rofecoxib increases the risk of serious coronary heart disease [23] and so do other selective COX-2 inhibitors [24–26], and the subsequent withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra) from the market, the future of using selective COX-2 inhibitors t…”
BackgroundNOD2-Mediated Innate Immune Signaling Regulates the Eicosanoids in Atherosclerosis
Liu, H., Zhang, X., Edfeldt, K., Nijhuis, M. M. O., Idborg, H., Bäck, M., Roy, J., Hedin, U., Jakobsson, P., Laman, J. D., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301715 · Cited by 56
The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors
Garthwaite, C. (2012) · American Economic Journal Applied Economics · doi:10.1257/app.4.3.116 · Cited by 56
5-Lipoxygenase Metabolic Contributions to NSAID-Induced Organ Toxicity
Burnett, B. P., & Levy, R. M. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0100-7 · Cited by 57
Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers
Kim, E. S., Hong, W. K., Lee, J. J., Mao, L., Morice, R. C., Liu, D. D., Jiménez, C. A., Eapen, G. A., Lotan, R., Tang, X., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0233 · Cited by 56
Renal and cardiovascular characterization of COX-2 knockdown mice
Seta, F., Chung, A. D., Turner, P. V., Mewburn, J. D., Yu, Y., & Funk, C. D. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90985.2008 · Cited by 57
Rheumatoid arthritis and cardiovascular disease: an update on treatment issues
Barbhaiya, M., & Solomon, D. H. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835fd7f8 · Cited by 62
Li, R. J., Li, M. L., León, E. J., Ng, C. W. K., Shindo, M. L., Manzione, K., Andersen, P. E., Clayburgh, D. R., Wax, M. K., & Chan, J. Y. K. (2018) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2018.1787 · Cited by 56
Tsai, W., Ou, T., Yen, J., Wu, C., & Tung, Y.-C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126347 · Cited by 59
“Unfortunately, the CVD risk of COX II inhibitors was further confirmed in two subsequent studies: the APC trial [8] and the APPROVE trial [9].”
Poor Adherence to Medication in Adults with Rheumatoid Arthritis: Reasons and Solutions
Elliott, R. A. (2008) · Disease Management & Health Outcomes · doi:10.2165/00115677-200816010-00003 · Cited by 63
“[122] A number of studies suggest that gesting that patients with established disease may be more adher- patients have difficulties understanding quantitative measures of ent, particularly to drugs showing no immediate symptom relief.”
BackgroundCelecoxib and cardiovascular risks
Brophy, J. M. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1005 · Cited by 64
“The subsequent demonstration of increased cardiovascular adverse events in the APPROVe trial removed any lingering doubts about the coronary toxicity of rofecoxib and resulted in its voluntary withdrawal [1].”
BackgroundReview of the cardiovascular safety of COXIBs compared to NSAIDS.
Moodley, I. (2008) · Europe PMC (PubMed Central) · Cited by 55
Moussa, O., Yordy, J. S., Abol‐Enein, H., Sinha, D., Bissada, N. K., Halushka, P. V., Ghoneim, M. A., & Watson, D. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1622 · Cited by 55
Naproxen-PC: A GI safe and highly effective anti-inflammatory
Lichtenberger, L. M., Romero, J. J., Dial, E. J., & Moore, J. E. (2009) · Inflammopharmacology · doi:10.1007/s10787-008-8047-2 · Cited by 55
“This concern was further corroborated in subsequent studies in both arthritic patients and patients taking lower chemo-preventive doses of these drugs leading to the withdrawal of most coxibs from the market and “black box” warnings placed on all NSAIDs ( Bresalier et al., 2005, Solomon et al., 2005, Nussmeier et al.,…”
Result6-C-(E-phenylethenyl)-Naringenin Suppresses Colorectal Cancer Growth by Inhibiting Cyclooxygenase-1
Li, H., Zhu, F., Chen, H., Cheng, K., Zykova, T. A., Oi, N., Lubet, R. A., Bode, A. M., Wang, M., & Dong, Z. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2245 · Cited by 55
Ungprasert, P., Srivali, N., & Thongprayoon, C. (2015) · Clinical Cardiology · doi:10.1002/clc.22502 · Cited by 61
Eicosanoids in the gastrointestinal tract
Wallace, J. L. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14178 · Cited by 55
“Both were hugely successful from a commercial standpoint, but less than 5 years after its launch, Merck removed rofecoxib fromworldwide markets because of evidence that it caused serious cardiovascular events (Bombardier et al., 2000; Bresalier et al., 2005).”
BackgroundChemoprevention in familial adenomatous polyposis: past, present and future
Bohan, P. M. K., Mankaney, G., Vreeland, T. J., Chick, R. C., Hale, D. F., Cindass, J. L., Hickerson, A. T., Ensley, D. C., Sohn, V. Y., Clifton, G. T., et al. (2020) · Familial Cancer · doi:10.1007/s10689-020-00189-y · Cited by 58
Day, R. O., & Williams, K. M. (2007) · Drug Safety · doi:10.2165/00002018-200730020-00001 · Cited by 55
Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point
Arber, N. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0167 · Cited by 48
Safety of Meloxicam in Aspirin-Hypersensitive Patients with Asthma and/or Nasal Polyps
Bavbek, S., Dursun, A. B., Dursun, E., Eryılmaz, A., & Mısırlıgil, Z. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000096000 · Cited by 55
Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression
Tseng-Rogenski, S. S., Gee, J., Ignatoski, K. W., Kunju, L. P., Bucheit, A. D., Kintner, H. J., Morris, D. S., Tallman, C. T., Evron, J. M., Wood, C. G., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090875 · Cited by 63
Zagani, R., Hamzaoui, N., Cacheux, W., de Reyniès, A., Terris, B., Chaussade, S., Romagnolo, B., Perret, C., & Lamarque, D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.039 · Cited by 55
Huang, W.-F., Hsiao, F., Wen, Y., & Tsai, Y.-W. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.009 · Cited by 55
Therapy of breast cancer with molecular targeting agents
Gasparini, G. M., Longo, R., Torino, F., & Morabito, A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi905 · Cited by 55
“In addition, coxibs increase blood pressure, decrease angiogenesis, and destabilize aterosclerotic plaques [54, 61–63].”
BackgroundResultCOX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran, P. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.042234 · Cited by 55
Hinz, B., Dormann, H., & Brune, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21540 · Cited by 56
Cardiomyocytes derived from human pluripotent stem cells for drug screening
Zeevi‐Levin, N., Itskovitz‐Eldor, J., & Binah, O. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.005 · Cited by 54
Rasmuson, A., Kock, A., Fuskevåg, O., Kruspig, B., Simón-Santamaría, J., Gogvadze, V. G., Johnsen, J. I., Kogner, P., & Sveinbjørnsson, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029331 · Cited by 54
“However, clinical studies have raised concerns about the potential adverse side effects of NSAIDs in adults [8].”
BackgroundCardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals
Fosbøl, E. L., Køber, L., Torp-Pedersen, C. T., & Gislason, G. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.501331 · Cited by 61
“The generalizability of the results from the trials when applied to the broad population of NSAID users is poor as most of the studies were performed in different patient settings characterized by certain diseases (Alzheimer’s disease [75], rheumatoid arthritis [5,76], polyps [14,17,22]), age (young excluded from anal…”
BackgroundMethodResultInfluentialZhou, Y., Crichton, I., Tang, S. Y., Hui, Y., Ricciotti, E., Levin, M. D., Lawson, J. A., Puré, E., & FitzGerald, G. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115313109 · Cited by 54
EP4 receptor as a novel promising therapeutic target in colon cancer
Karpisheh, V., Joshi, N., Zekiy, A. O., Beyzai, B., Hojjat‐Farsangi, M., Namdar, A., Edalati, M., & Jadidi‐Niaragh, F. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153247 · Cited by 55
Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target?
Bonvini, R. F., Hendiri, T., & Camenzind, E. (2005) · European Heart Journal Supplements · doi:10.1093/eurheartj/sui077 · Cited by 54
Zhao, Q. D., Hong, D., Zhang, Y., Sang, Y., Yang, Z., & Zhang, X. (2015) · Medicine · doi:10.1097/md.0000000000000731 · Cited by 58
“Secondly, MA based on published aggregated data tends to overestimate or underestimate treatment effects compared with individual patient data estimates.(48,49) In addition, it obviated a more comprehensive evaluation, such as adjusting for baseline characteristic and other differences that existed between the differe…”
ResultAdverse Cardiovascular Effects of Rofecoxib
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmc066260 · Cited by 54
Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal
Hinz, B., Renner, B., & Brune, K. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0619 · Cited by 53
Selective cyclooxygenase inhibition: its role in pain and anaesthesia
Langford, R. M., & Mehta, V. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.017 · Cited by 53
Hochberg, M. C., Fort, J. G., Svensson, O., Hwang, C., & Sostek, M. B. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.580340 · Cited by 56
Shah, S. R., & Mehta, V. (2011) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2011-130291 · Cited by 53
What’s in a gold standard? In defence of randomised controlled trials
Backmann, M. (2017) · Medicine Health Care and Philosophy · doi:10.1007/s11019-017-9773-2 · Cited by 53
“In a large study (Bresalier et al. 2005) however, it was discovered that the experimental group showed a larger number of cases of cardiovascular problems such as thrombotic events.”
BackgroundZatelli, M. C., Luchin, A., Piccin, D., Tagliati, F., Bottoni, A., Vignali, C., Bondanelli, M., & Uberti, E. C. D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1362 · Cited by 54
Bose, M., Hao, X., Ju, J., Husain, A., Park, S., Lambert, J. D., & Yang, C. S. (2007) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf071004r · Cited by 53
The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame
Salinas, G., Rangasetty, U. C., Uretsky, B. F., & Birnbaum, Y. (2007) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407301172 · Cited by 53
“In the APPROVe trial, the overall risk associated with rofecoxib did not appear to be significantly influenced by baseline or subsequent use of low-dose aspirin.(4) Studies published in 2002 have suggested that the nonselective COX inhibitor naproxen may reduce the risk of cardiovascular events (Table 2).”
BackgroundInfluentialMultistage carcinogenesis in Barrett's esophagus
Maley, C. C. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.018 · Cited by 62
NSAIDs for the Chemoprevention of Alzheimer’s Disease
Szekely, C. A., Town, T., & Zandi, P. P. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_11 · Cited by 62
“[113, 114] This led to withdrawal of rofecoxib from the market and to suspension of two cancer trials using celecoxib.”
BackgroundLoveridge, C. J., MacDonald, A. D., Thoms, H. C., Dunlop, M. G., & Stark, L. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210891 · Cited by 52
“However, these agents cannot be recommended for colorectal cancer prevention in healthy populations because of side-effect profiles (Bresalier et al., 2005; Wolfe et al., 1999).”
BackgroundKrishnaiah, Y. S. R., & Khan, M. A. (2012) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2012.696268 · Cited by 54
Precaution, cyclooxygenase inhibition, and cardiovascular risk
Ritter, J. M., Harding, I., & Warren, J. B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.007 · Cited by 52
Salvo, F., Antoniazzi, S., Duong, M., Molimard, M., Bazin, F., Fourrier‐Réglat, A., Pariente, A., & Moore, N. D. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.907792 · Cited by 55
Walker, C. (2018) · International Journal of Rheumatology · doi:10.1155/2018/1302835 · Cited by 69
“In a placebo-controlled polyp prevention trial, rofecoxib was associated with increased CV risk of thromboembolic outcomes (APPROVe) [51] and was subsequently withdrawn from the market by the manufacturer.”
BackgroundRichardson, H., Johnston, D., Pater, J. L., & Goss, P. E. (2007) · Current Oncology · doi:10.3747/co.2007.117 · Cited by 57
Lichtenberger, L. M., Romero, J. J., & Dial, E. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707176 · Cited by 56
“chronic use of Coxibs and other NSAIDs may increase a subject’s risk of developing a number of life-threatening cardiovascular/thrombotic adverse events (Mukherjee et al., 2001; Bresalier et al., 2005; Nussmeier et al., 2005; Solomon et al., 2005).”
BackgroundSafety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops
Hall, A. J., Babish, J. G., Darland, G. K., Carroll, B. J., Konda, V. R., Lerman, R. H., Bland, J., & Tripp, M. L. (2008) · Phytochemistry · doi:10.1016/j.phytochem.2008.02.001 · Cited by 52
“Previously published findings that three selective COX-2 inhibitors, rofecoxib, celecoxib and valdecoxib, are associated with increased risk of myocardial infarction in placebo controlled clinical trials (Bombardier et al., 2000; Bresalier et al., 2005; Nussmeier et al., 2005; Solomon et al., 2006) strongly implies th…”
BackgroundOrganizational disasters: why they happen and how they may be prevented
Choo, C. W. (2008) · Management Decision · doi:10.1108/00251740810846725 · Cited by 61
“An external panel overseeing the clinical trial recommended stopping the trial because patients on the drug were twice as likely to have a heart attack or stroke as those on a placebo (Bresalier et al., 2005).”
BackgroundHudson, M., Rahme, E., Richard, H., & Pilote, L. (2007) · Arthritis Care & Research · doi:10.1002/art.22614 · Cited by 52
Novel Targets for Antiinflammatory and Antiarthritic Agents
Kulkarni, R., Achaiah, G., & Sastry, G. N. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698945 · Cited by 58
“This cardiovascular adverse activity of refocoxib has been studied extensively by VIGOR (Vioxx Gastrointestinal Outcomes Research) and the study revealed that patients treated with rofecoxib have lower incidences of GI disturbance but number of heart attacks reported was higher [83-85] when compared with naproxane.”
ResultSchmassmann, A., Zoidl, G., Peskar, B. M., Waser, B., Schmassmann-Suhijar, D., Gebbers, J., & Reubi, J. C. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00416.2005 · Cited by 52
“Furthermore, increased cardiovascular events were observed in patients treated with selective COX-2 inhibitors (3).”
BackgroundFadaly, W. A. A., Elshaier, Y. A. M. M., Nemr, M. T. M., & Abdellatif, K. R. A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106428 · Cited by 52
Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy
Schlansky, B. L., & Hwang, J. H. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-008-2275-5 · Cited by 60
“market.(13,15) Research suggests that COX-2 inhibitors manifest cardiovascular toxicity because of an increase in the ratio of endothelial thromboxane A2 to platelet-derived prostacyclin, resulting in a prothrombotic state.”
Nimesulide as a promising neuroprotectant in brain ischemia: New experimental evidences
Candelario‐Jalil, E. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.03.003 · Cited by 54
“It isnoteworthy tomention that the increased toxicity of COX-2 inhibitors is observed after prolonged administration to patients at risk to develop cardiovascular events [37–40] and the relative cardiovascular risks of NSAIDs are similar inmagnitude to other currently prescribed therapies [41].”
BackgroundHabib, Z. A., Tzogias, L., Havstad, S. L., Wells, K. E., Divine, G., Lanfear, D. E., Tang, J. M., Krajenta, R. J., Pladevall, M., & Williams, L. K. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1722 · Cited by 53
3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer
Rakesh, K. S., Jagadish, S., Balaji, K. S., Zameer, F., Swaroop, T. R., Mohan, C. D., Jayarama, S., & Rangappa, K. S. (2015) · Inflammation · doi:10.1007/s10753-015-0247-5 · Cited by 51
“, myocardial infarction and stroke) [37, 38].”
Fracture pain—Traveling unknown pathways
Alves, C. J., Neto, E., Sousa, D. M., Leitão, L., Vasconcelos, D. M., da Silva, M. R., Alencastre, I. S., & Lamghari, M. (2016) · Bone · doi:10.1016/j.bone.2016.01.026 · Cited by 55
Arellano, F. M., Yood, M. U., Wentworth, C. E., Oliveria, S. A., Rivero‐Ferrer, E., Verma, A., & Rothman, K. J. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1343 · Cited by 51
“8) for the combined endpoint CHF, pulmonary oedema and cardiac failure.(12) The Kaplan–Meier curves for the cumulative incidence of the combined endpoint separated at approximately 5 months as opposed to 18 months for TE events.”
BackgroundAssessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva
Seminara, N. M., & Gelfand, J. M. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.01.001 · Cited by 52
Xiao, W. L. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1375 · Cited by 50
“Selective COX-2 inhibitors have reduced gastrointestinal related adverse events (39) but increased risk of cardiovascular diseases (19,40).”
BackgroundInflammation and Cancer: Chemical Approaches to Mechanisms, Imaging, and Treatment
Marnett, L. J. (2012) · The Journal of Organic Chemistry · doi:10.1021/jo300214d · Cited by 57
McCormick, D. L., Phillips, J. M., Horn, T. L., Johnson, W. D., Steele, V. E., & Lubet, R. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0151 · Cited by 50
“1 None (control) — 3/27 (11) 6/27 (22) 17/27 (63)”
Hinz, B., & Brune, K. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_3 · Cited by 50
Goldstein, J. L., Lowry, S., Lanza, F. L., Schwartz, H. I., & Dodge, W. E. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02912.x · Cited by 50
Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope
Medina, M. Á., Muñoz‐Chápuli, R., & Quesada, A. R. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00056.x · Cited by 54
Smith, F. M., Reynolds, J. V., Kay, E. W., Crotty, P. L., Murphy, J. O., Hollywood, D. P., Gaffney, E. F., Stephens, R. B., & Kennedy, M. J. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.07.961 · Cited by 50
O'Byrne, K. J., Danson, S. J., Dunlop, D. J., Botwood, N., Taguchi, F., Carbone, D. P., & Ranson, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2791 · Cited by 50
Cathcart, M. C., O'Byrne, K. J., Reynolds, J. V., O'Sullivan, J. N., & Pidgeon, G. P. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.09.004 · Cited by 51
“chronic use of selective COX-2 inhibitors at high concentrations has been associated with an increased risk of adverse cardiovascular events [20, 21, 26].”
BackgroundInfluentialTime‐trends in gastroprotection with nonsteroidal anti‐inflammatory drugs (NSAIDs)
Valkhoff, V. E., van Soest, E. M., Sturkenboom, M., & Kuipers, E. J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04281.x · Cited by 49
Hegazy, G. H., & Ali, H. I. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.030 · Cited by 49
Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in Italy
Motola, D., Vargiu, A., Leone, R., Conforti, A., Moretti, U., Vaccheri, A., Velo, G., & Montanaro, N. (2008) · Drug Safety · doi:10.2165/00002018-200831070-00006 · Cited by 49
Stroke risk and NSAIDs: an Australian population‐based study
Caughey, G. E., Roughead, E. E., Pratt, N. L., Killer, G. T., & Gilbert, A. L. (2011) · The Medical Journal of Australia · doi:10.5694/mja11.10055 · Cited by 49
Gwanyanya, A., Mačianskienė, R., & Mubagwa, K. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01479.x · Cited by 54
Effect of celecoxib combined with thoracic epidural analgesia on pain after thoracotomy
Sénard, M., DEFLANDRE, E. P., Ledoux, D., Roediger, L., Hubert, B., Radermecker, M., Libbrecht, D., & Joris, J. L. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq129 · Cited by 51
Sun, G., Zheng, Z., Lee, M., Xu, Y., Kang, S., Dong, Z., Wang, M., Gu, Z., Li, H., & Chen, W. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b00278 · Cited by 49
Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
Harry, J. A., & Ormiston, M. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772305 · Cited by 52
Ahmad, A. S., Kim, Y. T., Ahmad, M., Maruyama, T., & Doré, S. (2008) · Neurotoxicity Research · doi:10.1007/bf03033858 · Cited by 49
“However, recent reports show that these COX-2 inhibitors may carry potential side effects such as cardiac complications (Bresalier et al., 2005a; Graham et al., 2005; Baron et al., 2008).”
Liang, H., & Yuan, Q. (2011) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2011.604838 · Cited by 50
Hawkey, C. J. (2005) · Gut · doi:10.1136/gut.2005.065003 · Cited by 49
Klein, M. F. (2012) · PubMed · Cited by 56
Pawlosky, N. (2013) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163513481569 · Cited by 48
Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases
Ishiguro, H., & Kawahara, T. (2014) · BioMed Research International · doi:10.1155/2014/436123 · Cited by 48
“COX-2 selective NSAIDs have been shown to inhibit inflammation without damaging the gastric mucosa [8], although some have been linked with cardiovascular toxicity [9].”
Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review
Kroon, F. P. B., van der Burg, L. R. A., Ramiro, S., Landewé, R., Buchbinder, R., Falzon, L., & van der Heijde, D. M. F. M. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150721 · Cited by 48
Alrashed, F. A., Calay, D., Lang, M., Thornton, C. C., Bauer, A., Kiprianos, A. P., Haskard, D. O., Seneviratne, A. N., Boyle, J. J., Schönthal, A. H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24548-z · Cited by 49
NSAIDS and gastrointestinal cancer
Piazuelo, E., & Lanas, Á. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.06.001 · Cited by 51
The search for new COX-2 inhibitors: a review of 2002 – 2008 patents
Ramalho, T. C., Rocha, M. V. J., da Cunha, E. F., & Freitas, M. P. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903059125 · Cited by 48
“In fact, COX-1 has the structural features of a ‘housekeeping’ gene while COX-2 has those of an immediate early gene [30-32].”
BackgroundKapoor, M., Kojima, F., Qian, M., Yang, L., & Crofford, L. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610153200 · Cited by 48
Mok, C. C. (2006) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740600601526 · Cited by 50
“The selective cyclooxygenase (Cox) 2 inhibitors have recently been implicated in causing coronary arterial disease (87).”
Background
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.